By Inteledoc Expert Team | 10 min read | Medically reviewed by Dr. Nitin Jain, MBBS, MD EDIC — Inteledoc Medical Advisory Team
She used the word failure the way some patients use the word diagnosis — as if someone with more authority had already confirmed it. She had lost nearly eighteen kilos on Ozempic. She regained all of it within eleven months — the same month her prescription lapsed. She did not say her access stopped. She said she failed. That word — and the gap it represents between what medicine delivers and what patients need — is what this blog is about.
The Drug Is Not the Problem — What We Build Around It Is
Let us be clear from the start. GLP-1 medicines — Ozempic, Wegovy, Mounjaro, semaglutide, tirzepatide — are among the most clinically significant tools for weight management that medicine has produced in decades. The evidence is robust. The outcomes, in properly supervised programmes, are genuinely impressive. Inteledoc prescribes them. We will continue prescribing them.
The molecule is not the problem. The problem is everything medicine has failed to build around it — the missing conversations, the unmeasured variables, the unanswered questions that determine whether a patient’s success on the drug translates into a lasting change in their biology and their life.
This is a clinical perspective on the hunger that Ozempic quiets — and the hunger it cannot touch at all.
The Silence Nobody Warned Her About
On paper, she did everything the drug is designed to do. GLP-1 medicines act on receptors in the brain regions that register fullness and food reward — areas that operate far below conscious willpower. Her blood sugar markers improved. The scale moved eighteen kilos in the right direction. By every standard metric, this was a success story.
But no metric captured what stopped the moment the drug started working.
For eleven months, she told us, the noise went quiet. The constant negotiation over when she would eat next. The low background hum of food thoughts she had carried since her twenties. Gone. She did not miss the eighteen kilos nearly as much as she missed the silence — and when the silence ended, she had no explanation for why. No one had given her one.
This experience — the sudden, unexpected quiet that GLP-1 medicines can produce — is one of the most under-discussed aspects of treatment. For many patients, the food preoccupation they had carried for years was not simply an appetite. It was a coping mechanism. A regulator. A way of managing anxiety, evening emptiness, or emotional states that had no other outlet. When the drug quieted the signal chemically, it also removed the coping function — and nobody warned them that this would happen, what it would feel like, or what to do with the emotional space it left behind.
✗ THE GAP THAT MEDICINE KEEPS CREATING
If the drug is working and the numbers are improving, the patient is doing well. The prescription is the programme.
The prescription is not the programme. It is one element of a programme that — when properly constructed — also addresses body composition, nutritional strategy, behavioural adaptation, and the plan for what happens when the drug stops. When those elements are absent, the prescription becomes a temporary solution to a permanent biological condition, and the patient pays the price when the chemistry changes.
The Weight We Are Not Measuring — Body Composition
A patient loses eighteen kilos in five months on semaglutide. He celebrates the number. He should — the scale has moved significantly. But when body composition is finally assessed, a quarter of that total loss was muscle mass. No one had measured his muscle before he started, so no one could tell him what he was trading away while the scale kept dropping.
Muscle is not vanity tissue. It determines metabolic rate at rest — meaning that muscle lost during weight loss directly reduces how many calories the body burns every single day thereafter. It determines how well glucose is cleared from the bloodstream. It determines functional strength and injury resilience across decades of life. Losing significant muscle during GLP-1 treatment is not a cosmetic footnote. It is a silent decision — made by an unmonitored caloric deficit and a drug that suppresses appetite without specifying what to eat — about what kind of body that patient will inhabit for the rest of their life.
A decision that nobody asked them to make, because nobody was measuring the variable being lost.
What Proper Monitoring Should Include
Before any GLP-1 programme begins, body composition — the ratio of muscle mass to fat mass — should be established as a baseline. Not just weight. Not just BMI. Actual body composition, so that what is being lost during treatment can be tracked with precision. This number, once established, can be defended. Without it, it can only be guessed at — usually too late.
At Inteledoc, body composition assessment is part of our initial metabolic profiling. It gives us a baseline we protect throughout your programme through specific protein targets and exercise guidance. Read about our doctor-supervised approach here.
The Appetite That Disappears Too Well
GLP-1 medicines suppress appetite powerfully. For most patients, this is experienced as a relief — the relentless hunger that drove overeating simply reduces. But appetite suppression this strong creates a clinical problem that is rarely addressed directly: when appetite disappears, so does the body’s natural signal to consume the nutrients it still requires.
A patient who is eating very little because the drug has removed her appetite is not eating very little of everything she needs. She is eating very little protein. Very little dietary fibre. Very little of the micronutrients that support energy, immunity, bone health, and metabolic function. The drug changed what the body is asking for today. It did not change what the body has needed for the past thirty years — and it does not specify what to eat in its absence. She does not lack discipline. She lacks a protein target that nobody gave her, for a problem that nobody named.
✓ THE NUTRITIONAL PROTOCOL THAT CHNAGES THIS
Every Inteledoc patient on a GLP-1 programme receives a specific protein target from day one — typically 1.2 to 1.6 grams per kilogram of body weight daily — along with practical guidance on how to meet it when appetite has been significantly reduced. This is not an afterthought. It is the nutritional foundation that determines whether the weight lost is predominantly fat, or fat and muscle together. Plans from ₹1,500/month. See our programme plans from ₹1,500/month here.
What Food Noise Was Actually Doing
This is the conversation that most clinical appointments do not have time for — and that most programmes are not designed to have at all. But it matters more than almost anything else for long-term outcomes.
Food preoccupation that has run for decades does not appear out of nowhere. Somewhere along the way, it started doing something. Regulating a low-grade anxiety that had nowhere else to go. Filling a specific kind of evening silence. Giving a person something to manage when other things — a career, a relationship, a grief — needed managing and food was the only variable within reach.
GLP-1 medicines quiet receptors in the brain that neighbour the reward circuitry. Appetite and dopamine-linked craving share neural real estate. Turning down one can turn down the other. For a period, this feels like relief. The noise stops. The negotiation ends. The hands are still.
But quieting a biological signal chemically is not the same as resolving whatever built that signal over thirty years. The signal returns the moment the chemistry changes — and for patients who never had the conversation about what the noise was doing, its return feels like personal failure rather than a predictable clinical event with a planned response.
The Conversation That Should Happen Before the Prescription
When a clinician treats GLP-1 treatment as data rather than just a drug — when everything around the prescription is built as carefully as the prescription itself — several things change.
It starts with a body composition assessment before anything is lost — so muscle has a number that can be defended, not guessed at. It continues with a protein target delivered on day one, because appetite suppression means eating on purpose now requires effort the drug was supposed to remove. It includes direct guidance on resistance training — not as an aesthetic option, but as the clinical intervention that tells the body which tissue to preserve while the deficit runs.
And it includes a question that most clinical intake forms do not have a field for: What has this food noise been doing for you — and what do you expect to feel in the week it quiet?
Some patients answer immediately. Others need a moment. Either way, the answer belongs in the clinical record — not in the margins of an appointment that moved too fast to ask.
It also means saying the uncomfortable thing at the first visit, not the eleventh: this drug is effective, access can change, and if it stops, the body does not gently return to where it was. It defends the weight it lost, and it defends it hard. A plan for that moment should exist before that moment arrives — not be assembled inside it, while a patient is writing her own verdict about who failed whom.
The Plan Was the Problem — Not the Patient
She is back on the medication now, through a different access route. The weight is coming off
again — more slowly this time, with a protein target that is non-negotiable, a body composition scan that is tracked monthly, and a resistance training routine built into the programme from week one.
Nothing about her biology changed between the first round and this one. What changed was the conversation that happened before the prescription was written — the questions asked, the targets set, the plan made for the month when access might change again.
She was not the failure. The absence of a programme around the drug was the failure. And that is something medicine can fix — without changing the prescription at all.
✓ HOW INTELEDOC BUILDS THE COMPLETE PROGRAMME
Inteledoc's GLP-1 weight loss programme is designed specifically to address every gap described above. Comprehensive metabolic assessment before starting — including body composition. Specific protein targets from day one. Resistance training guidance integrated into the programme. Regular clinical monitoring of what is being lost — fat vs muscle. And an honest conversation about long-term access and maintenance planning before treatment begins.READ ABOUT OUR GLP-1 PROGRAMME HERE. See our programme plans from ₹1,500/month here.
Frequently Asked Questions
GLP-1 medicines work by suppressing hunger signals and improving insulin sensitivity. When the medicine stops, both effects reverse — hunger hormones return to previous levels and the metabolic adaptations that protect lost weight assert themselves. Research shows that patients who stop without a maintenance plan regain a significant proportion of lost weight within twelve months. This is a predictable biological event — not a personal failure — and it can be substantially mitigated by building lasting dietary and lifestyle habits during the treatment period and having a clear plan for the transition off medication.
Appetite suppression from GLP-1 medicines reduces overall caloric intake — which, without specific guidance, also reduces protein intake. Insufficient protein during a caloric deficit causes the body to break down muscle tissue alongside fat for energy. Prevention requires two things: a specific daily protein target (1.2–1.6g per kg of body weight) maintained even when appetite is low, and regular resistance training that signals the body to preserve muscle during the deficit. Both must be established from day one — not introduced after muscle loss has already occurred.
Food noise refers to the persistent, intrusive preoccupation with food — thoughts about what to eat next, when to eat, cravings, and the constant internal negotiation around eating — that many people with obesity or weight difficulties experience. It is driven by dysregulated hunger and reward signalling in the brain, including elevated ghrelin and disrupted leptin and dopamine pathways. It is a measurable biological phenomenon, not a character trait, and GLP-1 medicines reduce it directly by acting on the relevant brain receptors.
GLP-1 medicines reduce biologically driven hunger. They do not resolve the psychological or emotional functions that food may have developed over years — stress regulation, comfort, routine, boredom management, grief processing. When the biological noise quiets, the emotional functions food was serving may remain — requiring different, non-pharmacological support. Recognising this distinction is part of a comprehensive programme.
Yes — and Inteledoc considers this essential. A body composition baseline establishes the ratio of muscle to fat before treatment begins, allowing both you and your doctor to track specifically what is being lost during the programme. Without this baseline, it is impossible to know whether weight loss is coming predominantly from fat (the goal) or from a damaging mix of fat and muscle.
Yes — and not as an optional fitness add-on. Resistance training is the primary clinical intervention that signals the body to preserve muscle tissue during a caloric deficit. Without it, GLP-1-induced appetite suppression produces a deficit that the body meets partly through muscle breakdown. Two to three resistance sessions per week — even bodyweight exercises at home — meaningfully reduce muscle loss and produce significantly better body composition outcomes than GLP-1 treatment without resistance training.
A prescription provides the drug. Inteledoc’s programme provides the complete clinical framework that determines whether the drug produces lasting results: body composition assessment, specific protein targets, resistance training guidance, regular monitoring of what is being lost, dietary integration, and honest planning for the transition off medication. The prescription does not change. Everything around it does — and that difference is what produces outcomes that last.
This scenario should be planned for before it happens — not managed after. At Inteledoc, we discuss access sustainability and transition planning at the first consultation, not when the situation arises. For patients whose access changes, the programme response includes a structured dietary and exercise plan designed to maintain as much of the hormonal and metabolic benefit as possible, and a clinical pathway to resumed treatment where appropriate.
We ask the question before the prescription: what role has food played in your daily life beyond nutrition? What do you expect to feel when appetite changes significantly? These questions are not peripheral. They inform the programme — the level of behavioural support included, the monitoring frequency, and the maintenance planning. Where more dedicated psychological support is indicated, we facilitate appropriate referral as part of your clinical care.
Ready to start your doctor-supervised weight loss journey?
Inteledoc — India's first metabolonomics-based weight loss programme. Online & in-person in Gurugram. Plans from ₹1,500/month.
Book a consultation